IGF2BP3 (Gene)

Synonyms:CT98, ENTREZ:10643, HGNC:28868, IGF2BP3, IMP-3, IMP3, KOC, KOC1, MIM:608259, NM_006547, NP_006538, VICKZ3, XM_006715639, XM_011515089, XM_011515090, XM_011515091, XM_011515092, XM_011515093, XP_006715702, XP_011513391, XP_011513392, XP_011513393, XP_011513394, XP_011513395, insulin like growth factor 2 mRNA binding protein 3
Omim:OMIM:608259
Id:ENSG00000136231
Hgnc:HGNC:28868
Entrez:10643
Description:insulin like growth factor 2 mRNA binding protein 3
The protein encoded by this gene is primarily found in the nucleolus, where it can bind to the 5' UTR of the insulin-like growth factor II leader 3 mRNA and may repress translation of insulin-like growth factor II during late development. The encoded protein contains several KH domains, which are important in RNA binding and are known to be involved in RNA synthesis and metabolism. A pseudogene exists on chromosome 7, and there are putative pseudogenes on other chromosomes. [provided by RefSeq, Jul 2008]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View IGF2BP3's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with IGF2BP3.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using IGF2BP3.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for IGF2BP3.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with IGF2BP3.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.